



INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	
PTO Form 1449	

Atty Docket No. 114309-1017	Application No. 10/799,299
Applicant Gerald Horn	
Filing Date March 12, 2004	Group 1614

U.S. PATENT DOCUMENTS							
Examiner's Initials	Document Number	Publication Date	Inventor	Class	Subclass	Filing Date If Appropriate	
	4,443,441	04-1984	Galin				
	4,515,295	05-07-85	Dougherty				
	4,629,456	12-16-86	Edwards				
	4,834,727	05-30-89	Cope				
	4,906,613	03-06-90	Watkins				
	5,059,188	10-22-91	Goddard				
	5,134,124	07-28-92	Nisato et al.				
	5,514,118	05-07-96	Kummer et al.				
	5,584,823	12-17-96	Valberg				
	5,591,426	01-07-97	Dabrowski et al.				
	5,627,611	05-06-97	Scheiner				
	5,792,767	08-11-98	Meyer et al.				
	5,891,882	04-06-99	Meyer et al.				
	5,891,913	04-06-99	Sallmann et al.				
	5,895,654	04-2099	Hartford				
	6,046,207	04-04-00	Meyer et al.				
	09/675,988	09-29-00	Horn				
	09/705,526	11-03-00	Horn				
	6,291,498	09-18-01	Horn				
	6,420,407	07-16-02	Horn				
	2002/0082288	06-27-02	Horn				
	6,515,006	02-04-03	Horn				

FOREIGN PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Country	Class	Subclass	Translation Yes No

Examiner: 

Date Considered: 

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Atty Docket No. 114309-1017	Application No. 10/799,299
		Applicant Gerald Horn	
PTO Form 1449		Filing Date March 12, 2004	Group 1614

Examiner's Initials	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
MH	Bedford Laboratories, Phentolamine Mesylate for Injection, USP, May 1999.
	Van Alphen, G., <i>The adrenergic receptors of the intraocular muscles of the human eye</i> , Investigative Ophthalmology, June 1976, Vol. 15, No. 6, pp. 502-505.
	Yoshitomi, T., et al., Adrenergic Excitatory and Cholinergic Inhibitory Innervations in the Human Iris Dilator, Exp. Eye Res. 1998, Vol. 40, pp. 453-459.
	Lee, Y.C., et al., <i>Influence of dioptric correction and pupil size on visual function</i> , J. Cataract Refract. Surg., 2003, Vol. 29, pp. 769-777.
	Thordsen, J.E., et al., Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eye, April 25, 2003.
	Padma-Nathan, H., et al., <i>Long-term safety and efficacy of oral phentolamine mesylate (Vasomar) in men with mild to moderate erectile dysfunction</i> , International Journal of Impotence Research, August 2002, Vol. 14, No. 4, pp. 266-270.
	Heller, P.H., et al., <i>Autonomic components of the human pupillary light reflex</i> , Investigate Ophthalmology & Visual Science, Vo. 31, No. 1, January 1990, pp. 156-162.
	King, V.M., <i>Effects of mydriatics and a miotic on ocular discomfort and pupil responses</i> , Journal of the American Optometric Association, Vol. 47, No. 7, July 1976, pp. 937-942.
	Hill, C.E., et al., <i>Specificity of Innervation of Iris Musculature by Sympathetic Nerve Fibres in Tissue Culture</i> , Pflügers Arch., 1976, Vol. 361, pp. 127-134.
	Lograno, M.D., et al., <i>Receptor-responses in fresh human ciliary muscle</i> , Br. J. Pharmac., 1986, Vol. 87, pp. 379-385.
	Zetterström, C., et al., <i>Pharmacological Characterization of Human Ciliary Muscle Adrenoceptors in Vitro</i> , Exp. Eye Res., 1988, Vol. 46, pp. 421-430.
	Takayanagi, I., et al., <i>α_{1B}-Adrenoceptor Mechanisms in Rabbit Iris Dilator</i> , Japan. J. Pharmacol., 1992, Vol. 59, pp. 301-305.
	Ishikawa, H., et al., <i>Comparison of post-junctional α-adrenoceptors in iris dilator muscle of humans, and albino and pigmented rabbits</i> , Naun. Schmed., 1996, Vol. 354, pp. 165-172.
	Yu, Y., et al., <i>α_{1A}-Adrenoceptors Mediate Sympathetically Evoked Pupillary Dilation in Rats</i> , JPET, February 2002, Vol. 300, Issue 2, pp. 521-525.
	Benson, G.S., et al., <i>Is Phentolamine Stable in Solution with Papaverine</i> , The Journal of Urology, November 1988, Vo. 140, pp. 970-971.
✓	Hadzija, B.W., et al., <i>Physicochemical Stability of Papaverine Hydrochloride-phentolamine Mesylate Mixtures used for Intracavernous Injection: A Preliminary Evaluation</i> , The Journal of Urology, January 1988, Vol. 140, pp. 64-65.

Examiner:	Date Considered:
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary) PTO Form 1449		Atty Docket No. 114309-1017	Application No. 10/799,299
		Applicant Gerald Horn	
		Filing Date March 12, 2004	Group 1614

Examiner's Initials	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
MH	Soli, M., et al., <i>Vasoactive Cocktails for Erectile Dysfunction: Chemical Stability of PGE1, Papaverine and Phentolamine</i> , The Journal of Urology, August 1998, Vol. 160, pp. 551-555.
	Tu, Y.H., et al., <i>Stability of papaverine hydrochloride and phentolamine mesylate in injectable mixtures</i> , American Journal of Hospital Pharmacy, Vol. 44, November 1987, pp. 2524-2527.
	Wang, D.P., et al., <i>Degradation Kinetics of Phentolamine Hydrochloride in Solution</i> , Journal of Pharmaceutical Sciences, November 1988, Vol. 77, No. 11, pp. 972-976.
	H. Uusitalo, <i>An acute ocular inflammatory reaction induced by intravitreal bovine serum albumin in presensitized rabbits: the effect of phentolamine</i> , Acta. Ophthalmol. (Copenh), August 1994, Vol. 63, No. 4, pp. 636-642.
	H. Uusitalo, <i>The effect of autonomic receptor blockers on the ocular response to topical chemical irritation</i> , Acta. Physiol. Scand., May 1984, Vol. 121, No. 1, pp. 1-8.
	Davies, NM: <i>Biopharmaceutical considerations in topical ocular drug delivery</i> , Clin. Exp. Pharmacol. Physiol., 2000, Vol. 27, No. 7, pp. 558-562.
	Alster, Y., et al., <i>Dapiprazole for patients with night haloes after excimer keratectomy</i> , Graefe's Arch. Clin. Exp. Ophthalmol., 1996, Vol. 234, pp. S139-S141.
	McDonald II, J.E., et al., <i>Effect of brimonidine tartrate ophthalmic solution 0.2% on pupil size in normal eyes under different luminance conditions</i> , J. Cataract Refract. Surg., April 2001, Vol. 27, pp. 560-564.
	O'Brart, D.P.S., et al., <i>Disturbances in night vision after excimer laser photorefractive keratectomy</i> , Eve, 1994, Vol. 8, pp. 46-51.
	Fan-Paul, N.I., et al., <i>Night Vision Disturbances After Corneal Refractive Surgery</i> , Survey of Ophthalmology, November-December 2002, Vol. 47, No. 6, pp. 533-546.
	Connor, C.G., et al., <i>The clinical efficacy of Rēv-Eyes™ in reversing the effects of pupillary dilation</i> , Journal of the American Optometric Association, J. Am. Optom. Assoc., 1993, Vol. 64, pp. 634-636.
	O'Brart, D.P.S., et al., <i>Night vision after excimer laser photorefractive keratectomy: haze and halos</i> , European Journal of Ophthalmology, 1994, Vol. 4, No. 1, pp. 43-51.
	Nielsen, C.B., et al., <i>Effect of α- and β-receptor active drugs on corneal thickness</i> , Acta Ophthalmal., 1985, Vol. 63, pp. 351-354.
	Goodman & Gillman's <i>The Pharmacological Basis of Therapeutics</i> , (Ninth Edition) at pp. 225-232.
	Refractive Surgery, June 22, 2000, http://www/eyecarest.com/refractive_surgery.html .

Examiner:	Date Considered:
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Atty Docket No. 114309-1017	Application No. 10/799,299
PTO Form 1449		Applicant Gerald Horn	
		Filing Date 03-12-2004	Group 3761

U.S. PATENT DOCUMENTS

Examiner's Initials	Document Number	Publication Date	Inventor	Class	Subclass	Filing Date If Appropriate
MH	6,730,691	05-04-2004	Galin			

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Document Number	Publication Date	Country	Class	Subclass	Translation	
						Yes	No

Examiner's Initials	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
MH	Bedford Laboratories, Phentolamine Mesylate for Injection, USP, May 1999.
	Van Alphen, G., The adrenergic receptors of the intraocular muscles of the human eye, Investigative Ophthalmology, June 1976, Vol. 15, No. 6, pp. 502-505.
	Yoshitomi, T., et al., Adrenergic Excitatory and Cholinergic Inhibitory Innervations in the Human Iris Dilator, Exp. Eye Res. 1998, Vol. 40, pp. 453-459.
	Lee, Y.C., et al., Influence of dioptric correction and pupil size on visual function, J. Cataract Refract. Surg., 2003, Vol. 29, pp. 769-777.
	Thordsen, J.E., et al., Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eye, April 25, 2003.
	Padma-Nathan, H., et al., Long-term safety and efficacy of oral phentolamine mesylate (Vasomar) in men with mild to moderate erectile dysfunction, International Journal of Impotence Research, August 2002, Vol. 14, No. 4., pp. 266-270.

Examiner:	Date Considered:
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Atty Docket No. 114309-1017	Application No. 10/799,299
PTO Form 1449		DEC 27 2005 1449-15	Applicant Gerald Horn
		Filing Date 03-12-2004	Group 3761

Examiner's Initials	OTHER DOCUMENTS EXCLUDED (including Author, Title, Date, Pertinent Pages, Etc.)
NH	Heller, P.H., et al., Autonomic components of the human pupillary light reflex, Investigate Ophthalmology & Visual Science, Vo. 31, No. 1, January 1990, pp. 156-162.
	King, V.M., Effects of mydriatics and a miotic on ocular discomfort and pupil responses, Journal of the American Optometric Association, Vol. 47, No. 7, July 1976, pp. 937-942.
	Hill, C.E., et al., Specificity of Innervation of Iris Musculature by Sympathetic Nerve Fibres in Tissue Culture, Pflügers Arch., 1976, Vol. 361, pp. 127-134.
	Lograno, M.D., et al., Receptor-responses in fresh human ciliary muscle, Br. J. Pharmac., 1986, Vol. 87, pp. 379-385.
	Zetterström, C., et al., Pharmacological Characterization of Human Ciliary Muscle Adrenoceptors in Vitro, Exp. Eye Res., 1988, Vol. 46, pp. 421-430.
	Takayanagi, I., et al., α - _{1B} -Adrenoceptor Mechanisms in Rabbit Iris Dilator, Japan. J. Pharmacol., 1992, Vol. 59, pp. 301-305.
	Ishikawa, H., et al., Comparison of post-junctional α -adrenoceptors in iris dilator muscle of humans, and albino and pigmented rabbits, Naun. Schmed., 1996, Vol. 354, pp. 165-172.
	Yu, Y., et al., α - _{1A} -Adrenoceptors Mediate Sympathetically Evoked Pupillary Dilation in Rats, JPET, February 2002, Vol. 300, Issue 2, pp. 521-525.
	Benson, G.S., et al., Is Phentolamine Stable in Solution with Papaverine, The Journal of Urology, November 1988, Vo. 140, pp. 970-971.
	Hadzija, B.W., et al., Physicochemical Stability of Papaverine Hydrochloride-phenolamine Mesylate Mixtures used for Intracavernous Injection: A Preliminary Evaluation, The Journal of Urology, January 1988, Vol. 140, pp. 64-65.
✓	Soli, M., et al., Vasoactive Cocktails for Erectile Dysfunction: Chemical Stability of PGE1, Papaverine and Phentolamine, The Journal of Urology, August 1998, Vol. 160, pp. 551-555.

Examiner:	Date Considered:
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Atty Docket No. 114309-1017	Application No. 10/799,299
PTO Form 1449		Applicant Gerald Horn	
DEC 27 2005		Filing Date 03-12-2004	Group 3761

Examiner's Initials	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
MH	Tu, Y.H., et al., Stability of papaverine hydrochloride and phentolamine mesylate in injectable mixtures, American Journal of Hospital Pharmacy, Vol. 44, November 1987, pp. 2524-2527.
	Wang, D.P., et al., Degradation Kinetics of Phentolamine Hydrochloride in Solution, Journal of Pharmaceutical Sciences, November 1988, Vol. 77, No. 11, pp. 972-976.
	H. Uusitalo, An acute ocular inflammatory reaction induced by intravitreal bovine serum albumin in presensitized rabbits: the effect of phentolamine, Acta Ophthalmol. (Copenh), August 1994, Vol. 63, No. 4, pp. 636-642.
	H. Uusitalo, The effect of autonomic receptor blockers on the ocular response to topical chemical irritation, Acta. Physiol. Scand., May 1984, Vol. 121, No. 1, pp. 1-8.
	Davies, NM: Biopharmaceutical considerations in topical ocular drug delivery, Clin. Exp. Pharmacol. Physiol., 2000, Vol. 27, No. 7, pp. 558-562.
	Alster, Y., et al., Dapiprazole for patients with night haloes after excimer keratectomy, Graefe's Arch. Clin. Exp. Ophthalmol., 1996, Vol. 234, pp. S139-S141.
	McDonald II, J.E., et al., Effect of brimonidine tartrate ophthalmic solution 0.2% on pupil size in normal eyes under different luminance conditions, J. Cataract Refract. Surg., April 2001, Vol. 27, pp. 560-564.
	O'Brart, D.P.S., et al., Disturbances in night vision after excimer laser photorefractive keratectomy, Eve, 1994, Vol. 8, pp. 46-51.
	Fan-Paul, N.I., et al., Night Vision Disturbances After Corneal Refractive Surgery, Survey of Ophthalmology, November-December 2002, Vol. 47, No. 6, pp. 533-546.
	Connor, C.G., et al., The clinical efficacy of Rev-Eyes™ in reversing the effects of pupillary dilation, Journal of the American Optometric Association, J. Am. Optom. Assoc., 1993, Vol. 64, pp. 634-636.
	O'Brart, D.P.S., et al., Night vision after excimer laser photorefractive keratectomy: haze and halos, European Journal of Ophthalmology, 1994, Vol. 4, No. 1, pp. 43-51.

Examiner:	Date Considered:
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Atty Docket No. 114309-1017	Application No. 10/799,299
PTO Form 1449		Applicant Gerald Horn	
DEC 27 2005 MAILED RECEIVED U.S. PATENT AND TRADEMARK OFFICE		Filing Date 03-12-2004	Group 3761

Examiner's Initials	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
MH	Nielsen, C.B., et al., Effect of α - and β -receptor active drugs on corneal thickness, Acta Ophtahal., 1985, Vol. 63, pp. 351-354.
I	Goodman & Gillman's The Pharmacological Basis of Therapeutics, (Ninth Edition) at pp. 225-232.
	Nicola Iuglio, MD, Ocular Effects of Topical Application of Dapiprazole in Man, Glaucoma, 1984, Vol. 6, pp. 110-116.
✓	Chou B., et al., The Role of Pupil Size in Refractive Surgery, February, 2001, www.refractivesource.com/doctors/clinical_pearls/role_pupil.htm .
✓	Refractive Surgery, June 22, 2000, http://www.eyecarest.com/refractive_surgery.html .

Examiner:	Date Considered:
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Atty Docket No.	Application No.
	114309-1017	10/799,299
	Applicant	Gerald Horn
	Filing Date	Group
March 12, 2004	1614	

Examiner's Initials	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
MM	Chou B., et al., <i>The Role of Pupil Size in Refractive Surgery</i> , February, 2001, www.refractivesource.com/doctors/clinical_pearls/role_pupil.htm .

Examiner: Date Considered: 12/27/05
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.